Publications
Detailed Information
Human Sodium/Iodide Symporter-Mediated Radioiodine Gene Therapy Enhances the Killing Activities of CTLs in a Mouse Tumor Model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeon, Yong Hyun | - |
dc.contributor.author | Choi, Yun | - |
dc.contributor.author | Kim, Chul Woo | - |
dc.contributor.author | Kim, Young-Hwa | - |
dc.contributor.author | Lee, Jaetae | - |
dc.contributor.author | Chung, June-Key | - |
dc.contributor.author | Youn, Hyewon | - |
dc.date.accessioned | 2012-05-31T06:49:47Z | - |
dc.date.available | 2012-05-31T06:49:47Z | - |
dc.date.issued | 2010-01 | - |
dc.identifier.citation | MOLECULAR CANCER THERAPEUTICS; Vol.9 1; 126-133 | ko_KR |
dc.identifier.issn | 1535-7163 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76694 | - |
dc.description.abstract | We examined whether human sodium/iodide symporter (hNIS) radioiodine gene therapy can modulate the phenotype of cancer cells and enhance the killing activities of CTLs in a mouse tumor model. Various doses of I-131 (75, 300, 600, 1,200, and 2,400 mu Ci/5 mL) were incubated with hNIS-expressing colon cancer (CT26/hNIS) and parental cells (CT26), and numbers of MHC class I and Fas-expressing cells were determined by fluorescence-activated cell sorting (FACS). In addition, CT26/ hNIS or CT26 tumor-bearing mice were treated with 1,200 mu Ci of I-131, and percentages of MHC class I and Fas-expressing tumor cells were determined by FACS. The levels of tumor-infiltrating CD8+IFN gamma+ and CD11c+CD86+ cells and CTL killing activities were measured in CT26/ hNIS tumor-bearing mice (treated with PBS or 1,200 mu Ci of I-131) by FACS and lactate dehydrogenase assay, respectively. MHC class I and Fas gene expressions were markedly upregulated in CT26/ hNIS cells, but not in CT26 cells, in an I-131 dose-dependent manner. The level of MHC class I and Fas-expressing cancer cell were 4.5-fold and 2.1-fold higher in CT26/ hNIS tumors than in CT26 tumors, respectively (P < 0.01). Interestingly, numbers of tumor-infiltrating CD8+IFN gamma+ cells and CD11c+CD86+ cells were 5-fold and 2.5-fold higher in I-131-treated tumors than in PBS tumors, respectively (P < 0.001). Furthermore, CTL assays showed significantly more specific tumor cell lysis in I-131 tumors than in PBS tumors (P < 0.01). Our findings suggest that hNIS radioiodine gene therapy can generate tumor-associated immunity in tumor microenvironments and enhance the killing activities of CTLs. Mol Cancer Ther; 9(1); 126-33. (C) 2010 AACR. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | AMER ASSOC CANCER RESEARCH | ko_KR |
dc.title | Human Sodium/Iodide Symporter-Mediated Radioiodine Gene Therapy Enhances the Killing Activities of CTLs in a Mouse Tumor Model | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 전용현 | - |
dc.contributor.AlternativeAuthor | 최윤 | - |
dc.contributor.AlternativeAuthor | 김철우 | - |
dc.contributor.AlternativeAuthor | 김영화 | - |
dc.contributor.AlternativeAuthor | 윤혜원 | - |
dc.contributor.AlternativeAuthor | 이재태 | - |
dc.contributor.AlternativeAuthor | 정준기 | - |
dc.identifier.doi | 10.1158/1535-7163.MCT-09-0540 | - |
dc.citation.journaltitle | MOLECULAR CANCER THERAPEUTICS | - |
dc.description.citedreference | Jeon YH, 2008, MOL CANCER THER, V7, P2252, DOI 10.1158/1535-7163.MCT-08-0277 | - |
dc.description.citedreference | Chakraborty M, 2008, CLIN CANCER RES, V14, P4241, DOI 10.1158/1078-0432.CCR-08-0335 | - |
dc.description.citedreference | Jeon YH, 2007, INT J CANCER, V121, P1593, DOI 10.1002/ijc.22837 | - |
dc.description.citedreference | KIM HJ, 2007, CANC BIOL THER, V6 | - |
dc.description.citedreference | Chen L, 2006, J NUCL MED, V47, P854 | - |
dc.description.citedreference | Demaria S, 2005, INT J RADIAT ONCOL, V63, P655, DOI 10.1016/j.ijrobp.2005.06.032 | - |
dc.description.citedreference | Gulley JL, 2005, CLIN CANCER RES, V11, P3353 | - |
dc.description.citedreference | Garnett CT, 2004, CANCER RES, V64, P7985 | - |
dc.description.citedreference | Bubenik J, 2003, ONCOL REP, V10, P2005 | - |
dc.description.citedreference | Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167 | - |
dc.description.citedreference | Chakraborty M, 2003, J IMMUNOL, V170, P6338 | - |
dc.description.citedreference | Garcia-Lora A, 2003, J CELL PHYSIOL, V195, P346, DOI 10.1002/jcp.10290 | - |
dc.description.citedreference | Garcia-Lora A, 2003, EUR J IMMUNOGENET, V30, P177 | - |
dc.description.citedreference | Rosenberg SA, 2003, HUM GENE THER, V14, P709 | - |
dc.description.citedreference | Chung JK, 2002, J NUCL MED, V43, P1188 | - |
dc.description.citedreference | CHO JY, 2002, CURR GENE THER, V2, P393 | - |
dc.description.citedreference | Smyth MJ, 2001, NAT IMMUNOL, V2, P293 | - |
dc.description.citedreference | DE la Vieja A, 2000, PHYSIOL REV, V80, P1083 | - |
dc.description.citedreference | Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927 | - |
dc.description.citedreference | Gilboa E, 1999, CANCER IMMUNOL IMMUN, V48, P382 | - |
dc.description.citedreference | Watters D, 1999, IMMUNOL CELL BIOL, V77, P263 | - |
dc.description.citedreference | Mandell RB, 1999, CANCER RES, V59, P661 | - |
dc.description.citedreference | FERRONE S, 1995, IMMUNOL TODAY, V16, P487 | - |
dc.description.citedreference | KOJIMA H, 1994, IMMUNITY, V1, P357 | - |
dc.description.citedreference | KLEIN B, 1994, J NEUROSURG, V80, P1074 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.